Waters’ New UPLC Platform Meets Evolving Chromatography Needs

Article

The company’s next-generation ultraperformance liquid chromatography platform is designed to meet the evolving laboratory requirements for chromatographic performance.

Waters’ Acquity ultraperformance liquid chromatography (UPLC) PLUS Series-three new Acquity UPLC Systems-builds off of the success of the company’s Acquity UPLC separations platform. The company designed the new Acquity systems-UPLC H-Class PLUS, H-Class PLUS Bio, and IClass PLUS Systems-based, in part, on customer feedback.

The new systems offer enhanced flexibility, performance, and ease-of-use. They have various applications, including peptide mapping and routine product-release testing and can be used to meet academic, pharmaceutical, food, and chemical-industry laboratory research, development, and quality-control objectives.

The Acquity UPLC PLUS Systems debuted at the Analytica Conference, on April 10–13, 2018 in Munich, Germany.

“When introduced in 2004, the ACQUITY UPLC System transformed laboratory science by bringing dramatic business and scientific benefits to the analytical process. And it was met with overwhelming customer acclaim considering it had been 30 years since liquid chromatography saw such dramatic performance improvements,” said Eric Grumbach, director of product marketing, Chromatography Systems, Waters, in a company press release. “At Waters, innovation is about more than just performance. It’s about listening to the customer and continuously pushing our LC technology forward to find faster, simpler, and better ways to support the work that they do.”

Source: Waters

Recent Videos
Preeya Beczek, managing director and co-founder of Beczek.COM, chats about industry trends from 2024 and which of those might impact the industry in 2025, including the big trend of AI.
Kate Coleman, vice president regulatory affairs, quality and compliance, Arriello, chats about industry trends and technological advances.
William K. Oh, MD
Adam Sherlock, CEO of Qinecsa, discusses the changing political landscapes in the US and Europe and how that may affect the bio/pharma industry.
Adam Sherlock, CEO of Qinecsa Solutions
Buy, Sell, Hold: Cell and Gene Therapy
© 2025 MJH Life Sciences

All rights reserved.